The FDA has officially announced they will remove the longstanding boxed warning from estrogen-containing hormone therapy products. This decision finally aligns labeling with decades of high-quality menopause research. As a result, women now have clearer, more accurate information about their treatment options. This is a major step toward more accurate, compassionate menopause care.
What the Boxed Warning Claimed
The previous warning labels on prescription estrogen products claimed estrogen increased the risk of:
- Breast cancer
- Heart disease, heart attack, and stroke
- Blood clots
- Dementia
These warnings were based on early interpretations of the Women’s Health Initiative (WHI) study that we now know were inaccurately represented and incomplete, especially for women who start hormone therapy in their 40s and 50s.
Why the FDA Decision Matters
1. It Reduces Fear Rooted in Misinterpreted Science
Low-dose vaginal estrogen is not systemic and does not increase the risk of cardiovascular disease, stroke, blood clots, dementia, or breast cancer. In a 2024 study by McVicker et al., “Vaginal estrogen therapy use and survival in females with breast cancer,” the researchers found no increase in early mortality among breast cancer survivors.
Learn more about the safety of breast cancer and vaginal estrogen use.
2. It Expands Access to Effective Treatment
We also know that systemic estrogen can safely and effectively help women manage hot flashes, sleep disturbances, joint pain, brain fog, and genitourinary symptoms of menopause. Transdermal estrogen is often preferred because it does not increase the risk of blood clots above a woman’s baseline risk. In addition, data from the WHI trial showed that women using conjugated equine estrogen (CEE) alone, in women who had a hysterectomy, experienced a 23% reduction in breast cancer incidence and a reduction in breast cancer mortality.
Explore our perimenopause and menopause treatment options.
3. It Supports Individualized, Evidence-Based Care
Removing the boxed warning frees clinicians to provide accurate, up-to-date guidance with shared decision making rather than being constrained by outdated caution.
Advocacy That Made This Change Possible
Years of advocacy led to this important update. The Unboxing Menopause campaign from Let’s Talk Menopause mobilized more than 26,000 women, clinicians, and supporters to push for accurate labeling.
Learn more: https://letstalkmenopause.org/unboxingmenopause
In addition, the FDA Expert Panel on Menopause and Hormone Replacement Therapy reviewed the evidence and recommended removing the boxed warning on estrogen products. Experts who contributed include: Dr. Roberta Diaz Brinton • Dr. Kelly Casperson • Dr. Heather Hirsch • Dr. Howard Hodis • Dr. Barbara Levy • Dr. JoAnn Manson • Dr. Mary Jane Minkin • Dr. JoAnn Pinkerton • Dr. Rachel Rubin • Dr. Philip Sarrel • Dr. James Simon • Dr. Vonda Wright.
Their work helped ensure that estrogen labeling finally reflects what the science has shown for years.
The Bottom Line
Accurate information empowers women. The FDA’s removal of the boxed warning is a meaningful step toward better, safer, and more evidence-based menopause care. As always, women deserve treatment options grounded in science, clarity, and individualized support.
It’s a WIN for all of us!
Want Individualized Support or More Information?
📍 Schedule a consultation at Willow Women’s Health
📬 Sign up for our newsletter for more evidence-based tips on thriving in midlife.
